OrthoPediatrics (NASDAQ:KIDS) Major Shareholder Squadron Capital Llc Sells 10,131 Shares

OrthoPediatrics Corp. (NASDAQ:KIDS) major shareholder Squadron Capital Llc sold 10,131 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $23.10, for a total transaction of $234,026.10. Following the completion of the sale, the insider directly owned 6,526,633 shares of the company’s stock, valued at approximately $150,765,222.30. The trade was a 0.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Squadron Capital Llc also recently made the following trade(s):

• On Wednesday, August 26th, Squadron Capital Llc sold 18,000 shares of OrthoPediatrics stock. The shares were sold at an average price of $24.28, for a total value of $437,040.00.
• On Tuesday, August 25th, Squadron Capital Llc sold 16,300 shares of OrthoPediatrics stock. The stock was sold at an average price of $24.74, for a total value of $403,262.00.
• On Monday, August 24th, Squadron Capital Llc sold 4,000 shares of OrthoPediatrics stock. The shares were sold at an average price of $25.75, for a total transaction of $103,000.00.

OrthoPediatrics Trading Down 1.3%

Shares of NASDAQ KIDS traded down $0.31 during mid-day trading on Tuesday, reaching $23.00. The company had a trading volume of 139,797 shares, compared to its average volume of 173,766. The stock has a market cap of $600.53 million, a price-to-earnings ratio of -13.69 and a beta of 0.98. OrthoPediatrics Corp. has a 52 week low of $14.42 and a 52 week high of $26.74. The business’s 50-day moving average is $21.52 and its 200-day moving average is $18.72. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28.

OrthoPediatrics (NASDAQ:KIDS) last issued its earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. The business had revenue of $70.51 million for the quarter, compared to the consensus estimate of $68.21 million. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. Equities analysts expect that OrthoPediatrics Corp. will post -1.14 earnings per share for the current year.

Institutional Investors Weigh In On OrthoPediatrics

Several institutional investors have recently bought and sold shares of KIDS. California State Teachers Retirement System increased its position in shares of OrthoPediatrics by 397.1% during the second quarter. California State Teachers Retirement System now owns 4,553 shares of the company’s stock worth $87,000 after purchasing an additional 3,637 shares in the last quarter. Nantahala Capital Management LLC purchased a new position in OrthoPediatrics during the 2nd quarter worth $4,636,002. Grandeur Peak Global Advisors LLC acquired a new position in OrthoPediatrics during the 2nd quarter valued at about $954,000. Bank of America Corp DE purchased a new stake in OrthoPediatrics in the second quarter valued at about $268,000. Finally, AWM Investment Company Inc. acquired a new stake in OrthoPediatrics in the second quarter worth about $4,537,000. 69.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on KIDS. TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. Truist Financial set a $22.00 price objective on shares of OrthoPediatrics in a research note on Wednesday, August 5th. BTIG Research raised their target price on shares of OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Piper Sandler reaffirmed an “overweight” rating and issued a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Finally, Weiss Ratings upgraded shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $26.44.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.